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Introduction
Myocardial infarction (MI) is followed by diverse cardiac 
structural changes including cardiomyocyte hypertrophy, 
enhanced formation of interstitial fibrosis as well as loss of 
cardiomyocytes due to apoptosis.1–3 This post-MI remodel-
ling process aims at compensating the loss of cardiac tissue 
after MI but is not necessarily able to restore the functional 
capacity of the heart back to normal4 depending on the size 
of the initial myocardial injury. After a large MI, the chronic 
congestive cardiac failure that ensues is characterized by 
continuous loss of cardiomyocytes, progressive cardiac 
dilatation, further deterioration of cardiac function and, 
finally, poor prognosis.5,6
The traditional concept has long been that mature car-
diomyocytes have lost their capacity to divide and are 
thereby unable to replace and repair the loss of cardiac 
tissue after myocardial infarction. On the other hand, it 
has been calculated that continuous apoptotic loss 
of cardiomyocytes at a rate of 0.1–0.3% would lead to 
absolute decrease in the amount of cardiac cells and loss 
of cardiac tissue within a couple of years unless new car-
diac cells were generated.7
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Therefore, it has been suggested that a regenerative sys-
tem must exist to replace the apoptotic loss of cardiac cells. 
Supporting this concept, recent research has indeed been 
able to show that the heart possesses regenerative capacity. 
The heart contains resident progenitor cells (cardiac stem 
cells) which can be activated to proliferate and to form new 
cardiac structures after myocardial injury.8–10
The renin–angiotensin system (RAS) has a pivotal role 
both in the post-MI cardiac remodelling process and in the 
pathogenesis of cardiac failure.11 Local cardiac RAS is acti-
vated in the infarcted myocardium12–14 and is also involved 
in the remodelling process of the non-infarcted cardiac tis-
sue after MI.15 Numerous clinical trials after MI and in 
patients with chronic heart failure have demonstrated ben-
efits of RAS-blockade either with angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin type 1 (AT1) 
receptor antagonists in the treatment of these patient 
groups.16–18 However, cardiovascular morbidity and mor-
tality are still significantly higher than expected in patients 
with heart failure as compared with normal ageing despite 
current optimal medical therapy including a RAS-inhibitor 
and a beta-blocker. Thus, additional treatment strategies are 
needed to further reduce the excess morbidity in these 
patients. Findings on cardiac stem/progenitor cells have 
opened up completely new possibilities to prevent and treat 
heart failure after cardiac injury. By combining measures to 
enhance endogenous cardiac regeneration19,20 with current 
established treatments for cardiac diseases the treatment 
results could improve significantly in the future. At the 
same time, more research is also needed to understand how 
current cardiovascular drugs influence the cardiac regener-
ative process.
At present the role of intracardiac RAS in the regula-
tion of cardiac regeneration and repair after MI is not fully 
understood.11 Even less is known about the effects of 
RAS-blockade on proliferation and kinetics of cardiac 
progenitor cells after myocardial injury. Angiotensin II 
may have both beneficial and potentially harmful cardiac 
effects after MI including growth and cell proliferation 
promoting, pro-inflammatory, pro-fibrotic and angiogene-
sis-stimulating effects.21,22 Therefore, more information is 
needed on the effects of angiotensin blockade on the car-
diac regenerative process after myocardial injury. The 
present study was undertaken to explore the effects of 
losartan, a selective AT1-receptor antagonist, on forma-
tion of new cardiomyocytes and vascular structures as 
well as on left ventricular remodelling after experimental 
MI in rats. Ki67-staining was used to show and quan-
tify proliferative cells and bromodeoxyuridine (BrdU)-
staining19,23 to identify newly formed cells. By giving 
BrdU after induction of myocardial infarction it is possi-
ble to quantify the amount of newly formed cardiomyo-
cytes and other cardiac cells, including vascular cells, as 
judged by positivity for BrdU and cell-specific markers in 
immunohistochemical stainings.
Materials and methods
Experimental myocardial infarction and 
treatments
The left anterior descending coronary artery (LAD) was 
ligated to produce MI. The experimental protocol was 
approved by Helsinki University Laboratory Animal 
Committee and the Province State Office of Southern 
Finland. Rats were anaesthetized with medetomidine 
(Domitor, Orion, Turku, Finland; 0.5 mg/kg subcutane-
ously (s.c.)) and ketamine (Ketalar, Parke Davis, 
Barcelona, Spain; 60 mg/kg s.c.). The rats were con-
nected to a respirator through a tracheotomy and the 
heart was exposed through a lateral thoracotomy (in the 
tenth intercostal space). The LAD was ligated about 3 
mm from its origin and the thorax was closed. The anaes-
thesia was partially antagonized with antipamezole 
hydrochloride (Antisedan, Orion; 0.80 mg/kg intramus-
cularly (i.m.)). The body temperature was maintained 
stable using a thermal plate throughout the operation. 
Rats were hydrated post-operatively with 5 ml of physi-
ological saline s.c. Buprenorphin (Temgesic, Schering-
Plough, Brussels, Belgium; 0.015 mg/rat s.c.) was given 
twice a day for three days for analgesia. The sham-operated 
rats underwent the same procedure, except for the ligation 
of the coronary artery.
A total of 101 Wistar male rats (Harlan Laboratories, 
Boxmeer, Netherlands) weighing 228–321g were used in the 
study. Rats were randomized into four groups (MI+losartan, 
MI+vehicle, sham+losartan and sham+vehicle) 12–16 h 
after the operation. The number of rats in each group and 
time point was 10–12. Losartan (MK0954, Merck & Co. 
Inc., Whitehouse Station, NJ, USA) was mixed into the pow-
dered food 250 mg/kg. Mean estimated dose was 40 mg/kg. 
The rats in the vehicle groups were given the same food 
without losartan. 5-bromo-2′-deoxyuridine (BrdU, Sigma-
Aldrich, Saint Louis, MO) was added to drinking water 1 g/l. 
Consumption of food and water was measured to calculate 
the actual doses. The perioperative mortality rate was 9.87 % 
and two rats died later during the experiment.
Rats were sacrificed at one or four weeks after the oper-
ation under pentobarbital (Mebunat, Orion; 55 mg/kg i.p.) 
anaesthesia. The relative weight (mg/g body weight) of the 
heart, lungs and kidneys were determined. Blood samples 
were collected into tubes containing Na2EDTA and apro-
tinin. The heart was cut into 2 mm transverse slices below 
the point where the coronary artery was ligated. The myo-
cardial samples were either frozen in liquid nitrogen and 
stored at −80oC or fixed in 4% neutral buffered formalin for 
24 h, embedded in paraffin.
Echocardiography
Transthoracic echocardiography was performed at one 
and four weeks (Toshiba Ultrasound, Tokyo, Japan) under 
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isoflurane anaesthesia (AGA, Riihimäki, Finland) in a 
blinded fashion by the same technician.
Plasma renin activity
Plasma renin activity was determined using angiotensin I 
radioimmunoassay (RIA) kit (Diasorin, Vercelli, Italy) 
according to the manufacturer’s instructions.
Western blotting
Protein levels in the infarct areas of rat hearts were studied 
using Western blotting as described.24 The membranes were 
probed with anti-hepatocyte growth factor (HGF-α, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), anti-vascular 
endothelial growth factor A (VEGF-A, rabbit polyclonal, 
Millipore, Temecula, CA, USA).
Infarct size
The infarct size was determined planimetrically from trans-
verse left ventricular sections stained with Weigert van 
Gieson as the ratio of the infarct tissue or scar to the length 
of the entire left ventricle as described.25
Immunohistochemical analysis
To identify cardiomyocytes, vascular structures, new 
(BrdU+) cells, apoptosis and c-Kit positive cells immuno-
fluorescent staining was performed. Transverse paraffin 
sections (5 µm) from the mid-ventricular level of rat hearts 
were used in immunohistochemistry. Two sections per rat 
heart were studied. To obtain quantitative results, the pro-
portions of the infarct area, border area and remote non-
infarcted myocardium of the left ventricle were determined 
and the results were counted for each of these areas. Viable 
myocardium extending 0.5–1 mm from the infarct area was 
considered to represent the infarct border area. The non-
infarcted myocardium over 1 mm from the infarct area was 
determined as remote area. In all sections nuclei were 
stained with 4′6-diamino-2-phenylindole (DAPI) (Life 
Technologies, Molecular Probes, Carlsbad, CA, USA). The 
immunolabelled sections were examined with a Leica DM 
4500B fluorescent microscope (Leica Microsystems, 
Wetzlar GmbH, Wetzlar, Germany) or Zeiss LSM 510 Meta 
confocal microscope.
Caspase-3 (Casp3) was used as a marker for apoptosis. 
Double staining with antibodies for Casp3 (rabbit poly-
clonal, Cell Signaling, Danvers, MA, USA) and cardiac 
myosin heavy chain (MHC, mouse monoclonal, Millipore, 
Upstate, Billerica, MA, USA) was utilized. All the Casp3+ 
and MHC+ cardiomyocytes were counted from the whole 
section in sham-operated rats or the remote and border area 
of each section in infarcted rats and compared with the 
amount of all myocytes in the same area. The amount of 
total myocytes in a certain section was evaluated by count-
ing the amount of myocytes per mm2 (from 6–15 randomly 
selected microscopic fields) and comparing this with the 
size of the whole area.
To identify capillaries and arteries in the infarct area, 
border area and remote myocardium, double staining for 
α-smooth muscle actin (α-SMA, mouse monoclonal, Dako 
Cytomation, Glostrup, Denmark) and von Willebrand 
factor (vWF, rabbit polyclonal, Millipore, Chemicon, 
Billerica, MA, USA) was performed. The vascular and 
capillary densities were analysed from 6–15 randomly 
selected microscopic fields (200× or 400× magnification) 
photographed from each of the infarct, border and remote 
areas.
BrdU positivity was used to identify cells formed 
after coronary ligation or sham operation. The cells were 
stained using anti-BrdU (mouse monoclonal, Roche 
Diagnostics, Mannheim, Germany). Double staining 
with antibodies for BrdU and troponin I (rabbit poly-
clonal, Santa Cruz Biotechnology, Santa Cruz, CA) was 
performed to identify newly formed cardiomyocytes. 
BrdU+ cells and cardiomyocytes (BrdU+, troponin+) 
were counted in the same manner as described above for 
Casp3+ cell counting. In addition the number of newly 
formed vascular structures was analysed using double 
staining for BrdU and vWF. C-Kit positive cells were 
stained with c-Kit antibody (rabbit polyclonal, Dako 
Cytomation) and counted.
For Ki67 staining, samples were embedded in paraffin 
and cut into 4-µm-thick sections. Immunostaining was per-
formed using a Ventana Discovery Automate (Ventana 
Medical Systems Inc., Tucson, AZ, USA). Ki67 (anti-Ki67; 
Thermo Fischer Scientific, Labvision, Fremont, CA, USA) 
proliferation-associated antigens were double stained for 
myocytes using antibody for tropomyosin (Labvision). The 
Ki67+ myocytes were manually counted from the border 
and the remote area of each section and compared with the 
amount of all myocytes in the border or remote area. The 
number of total myocytes in a certain section was evaluated 
by counting the number of myocytes per mm2 (from 6–15 
randomly selected microscopic fields) and comparing it 
with the size of the whole area.
Cardiomyocyte size was analysed by measuring the 
cross-sectional area of 100 cardiomyocytes per heart by 
using ImageJ software. The cardiomyocytes cut in short 
axis with a visible nucleus were measured from tissue sec-
tions stained with anti-MHC and DAPI.
The secondary antibodies were Alexa Fluor 488- 
conjugated goat anti-mouse or donkey anti-goat IgG 
(Molecular Probes), Alexa Fluor 546-conjugated goat anti-
rabbit IgG (Molecular Probes) and tetramethyl rhodamine 
isothiocyanate (TRITC)-conjugated swine anti-rabbit IgG 
(Dako Cytomation).
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Statistical analysis
Data are presented as mean ± SEM. Differences between 
groups were analysed by one-way analysis of variance 
(ANOVA) followed by the Tukey test or Student’s t test or 
nonparametric Kruskall–Wallis test followed by Mann–
Whitney U test. Differences were considered significant at 
p value <0.05
Results
Body weight, infarct size, cardiac weight and 
pulmonary weight
There were no statistical differences between groups in 
body weight either before the operation or at the studied 
time points. The infarct size did not differ between LAD-
ligated groups (MI vehicle group versus losartan treated MI 
rats) (Table 1).
Relative heart weight was significantly higher in the 
infarcted rats compared with sham operated controls at both 
time points. In the losartan treated MI rats, the heart index 
was lower (2.71±0.064 g/kg, p<0.001) compared with vehi-
cle treated-rats with MI (3.501±0.173) at four weeks (Table 
1). The relative lung weight was higher in infarcted rats com-
pared with sham-operated rats at one week (Table 1).
Cardiac function (echocardiography)
When comparing MI and sham operated groups, expected 
echocardiography changes were found. At four weeks both 
end diastolic and systolic volumes increased significantly 
in MI rats (Table 2). In addition, fractional shortening was 
lower and ejection fraction tended to be lower in MI rats at 
week 4. No statistically significant differences were found 
between losartan versus vehicle treated MI rats at weeks 1 
or 4 (Table 2).
Cardiomyocyte hypertrophy
At week 4 the myocyte cross-sectional area increased in MI 
groups compared with sham operated groups (Table 1). In 
losartan treated MI rats the myocyte cross-sectional area 
tended to be smaller compared with vehicle treated MI rats 
but differences were significant neither at week 1 nor at 
week 4.
Plasma renin activity
As expected, treatment with the angiotensin type 1 antagonist 
losartan stimulated plasma renin activity (Table 1), reflecting 
blockade of the RAS. There were no differences between 
sham operated and MI groups in plasma renin activity.
Table 1. Body weight, infarct size, relative heart weight, myocyte cross-sectional area, relative lung weight and plasma renin activity 
one and four weeks after sham operation or coronary artery ligation.
Group
(number of rats)
Body weight
(g)
Infarct size
(%)
Relative heart weight
(g/kg)
Myocyte cross-
sectional area (mm2)
Relative lung weight
(g/kg)
Plasma renin activity
(ng/ml per h)
Week 1
Sham + vehicle
(n = 10)
279±7.37 2.93±0.044 360±15.3 4.743±0.120 19.2±2.10
Sham + losartan
(n = 10)
280±6.39 2.72±0.040b n.d. 4.71±0.079 33.0±2.99b
MI + vehicle
(n = 9)
283±5.89 40.4±6.18 3.45±0.160a 362±15.1 5.62±0.315b 15.5±2.04
MI + losartan
(n = 10)
280±6.02 40.3±5.69 3.36±0.148a 337±18.6 5.47±0.239c 24.9±2.26e
Week 4
Sham + vehicle
(n = 12)
295±3.45 2.72±0.042 328±16.6 4.31±0.095 16.7±2.48
Sham + losartan
(n = 10)
300±5.65 2.52±0.055a n.d. 4.41±0.093 49.2±3.46c
MI + vehicle
(n = 10)
298±6.29 38.1±6.05 3.501±0.173c 439±19.3b 5.79±0.889 17.7±1.79
MI + losartan
(n = 11)
303±5.84 33.9±4.26 2.71±0.064f 409±19.9a 4.40±0.103 41.2±4.48e
Values are mean ± SEM.
ap<0.05 versus vehicle treated sham group at corresponding time point.
bp<0.01 versus vehicle treated sham group at corresponding time point.
cp<0.05 versus vehicle treated MI group at corresponding time point.
dp<0.01 versus vehicle treated MI group at corresponding time point.
ep<0.001 versus vehicle treated MI group at corresponding time point.
n.d.: not determined; MI: myocardial infarction.
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Cardiomyocyte regeneration, neo-
vascularization and apoptosis
The number of BrdU+ cardiomyocytes (Figure 3(a) and 3(b)) 
increased four- to eight-fold (p<0.05 and p<0.01 versus sham) 
in the infarct border zone after MI at weeks 1 and 4 (Figure 
1(a)). Losartan treatment neither stimulated nor prevented 
neoformation of cardiomyocytes after MI (Figure 1(b)).
The number of proliferative (Ki67+) cardiomyocytes 
(Figure 3(d)) increased five-fold in the infarct border zone 
at week 1 (p<0.05 versus sham) after MI (Table 3). The 
number of Ki67+ cardiomyocytes did not differ between 
losartan and vehicle treated MI rats. Only sporadic c-Kit+ 
progenitor cells could be detected in losartan and vehicle 
treated groups and therefore statistical differences between 
the groups could not be evaluated.
Compared with vehicle treated MI rats, losartan treatment 
induced formation of new vascular structures (Figure 3(c)) in 
the infarct border zone. Capillary density (vWF+) was 1.3-
fold higher in the losartan MI group (1418±61.2, vessel 
count per mm2) compared with vehicle treated MI rats 
(1072±160, p<0.05, Table 4) at week 4. The amount of newly 
formed vessels (BrdU+, α-SMA+) was five-fold higher in 
the losartan treated MI group (3.85±1.19, % of total) versus 
the vehicle treated MI group (0.749±0.508, p<0.05, Table 4).
The amount of all BrdU+ cells (including also non-
cardiomyocytes) was increased in the infarct border zone 
of MI rats at week 1 compared with sham operated con-
trols (p<0.05, Figure 1(b)). At week 4 the amount of BrdU+ 
cells increased also in the remote zone (p<0.01 versus 
sham). Losartan treatment did not affect the number of all 
BrdU+ cells in the infarct border zone (Figure 2(a)). At 
week 4, the total number of new cells in the remote zone 
tended to be lower in the losartan MI group (3.11±0.53%) 
compared with vehicle treated MI rats (5.16 ±1.02%, 
p=0.08, Figure 2(b)).
The number of apoptotic (Casp3+) cells was higher 
mainly in the infarct border zone as compared with sham-
operated controls (p<0.05, Table 3). The rate of apoptosis 
did not differ between losartan versus vehicle treated MI 
groups.
HGF-α and VEGF-A
No differences in HGF-α (HGF-α/actin: MI+losartan 1.22± 
0.32 at week 1, 1.01+0.16 at week 4 vs. MI+vehicle 
1.00±0.28, 1.15±0.37, respectively) and VEGF-A (VEGF-A/
actin: MI+losartan 1.10±0.53 at week 1, 1.33±0.25 at week 
4 vs. MI+vehicle 1.50±0.38, 1.48±0.31, respectively) levels 
were found between losartan and vehicle treated MI groups 
at weeks 1 or 4.
Discussion
Formation of new cardiomyocytes increased markedly in 
the infarct border zone after coronary artery ligation, con-
firming previous findings on regenerative potential of the 
heart. Several studies have shown that the heart contains 
stem/progenitor cells that are capable of activating, prolif-
erating and forming new cardiac cells and structures after 
myocardial damage.8-10,19 We used continuously adminis-
tered BrdU, an easily detectable compound for DNA-
labelling during cell division,23 to obtain a cumulative 
estimate of new cardiomyocytes and other newly formed 
cardiac cells during the post MI period. We found that sig-
nificant amounts of BrdU-labelled cardiomyocytes and 
vascular structures are formed in the infarct border zone 
after MI but not in the remote, non-infarcted myocardium 
compared with sham operated control rats. The formation 
of BrdU positive cardiomyocytes continued throughout the 
four week post-MI study period, being three-fold higher at 
Table 2. Cardiac function determined by echocardiography at one and four weeks after sham operation or coronary artery 
ligation.
FS (%) EF (%) CO(ml/min) EDV (ml) ESV (ml) IVSTd (mm) IVSTs (mm) LVIDd LVIDs
Week 1
Sham + vehicle (n = 12) 31.6±1.88 64.1±2.9 166±9.8 1.95±0.05 0.36±0.05 1.37±0.05 2.10±0.07 7.51± 0.20 5.17±0.26
Sham + losartan (n = 9) 35.3±2.30 68.9±2.8 196±19.1 1.97±0.12 0.30±0.04 1.37±0.05 2.10±0.11 7.38± 0.24 4.82±0.29
MI + vehicle (n = 10) 27.9±2.75 59.9±4.0 181±11.1 1.77±0.22 0.55±0.11 1.35±0.09 2.06±0.20 8.11± 0.28 5.91±0.42
MI + losartan (n = 11) 27.6±1.65 59.0±2.6 196±10.4 1.82±0.14 0.53±0.05a 1.36±0.07 2.00±0.14 8.24± 0.13 5.99±0.22
Week 4
Sham + vehicle (n = 12) 30.8±1.45 63.2±2.2 185±12.0 1.09±0.05 0.41±0.03 1.29±0.04 1.95±0.05 7.88±0.13 5.47±0.16
Sham + losartan (n = 9) 31.5±1.57 63.8±1.7 182±9.0 1.06±0.04 0.39±0.03 1.22±0.05 1.97±0.12 7.84±0.10 5.38±0.16
MI + vehicle (n = 10) 22.5±3.51a 52.4±6.0 199±20.9 1.62±0.14b 0.90±0.19b 1.26±0.08 1.77±0.22 8.99±0.27b 7.11±0.52b
MI + losartan (n = 11) 23.3±2.39a 52.3±4.2 173±16.5 1.27±0.06a 0.64±0.08a 1.27±0.05 1.82±0.14 8.34±0.15a 6.41±0.28a
Values are mean + SEM.
ap<0.05 versus vehicle treated sham group at corresponding time point.
bp<0.01 versus vehicle treated sham group at corresponding time point.
MI: myocardial infarction; EF: ejection fraction; CO: cardiac output; FS: fractional shortening; EDV: end diastolic volume; ESV: end systolic volume; IVSTd: diastolic intraven-
tricular septum thickness; IVSTs: systolic intraventricular septum thickness; LVIDd: diastolic left ventricle internal dimension; LVIDs: systolic left ventricle internal dimension.
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week 1 and eight-fold higher at week 4 compared with 
sham operated controls. This finding was confirmed by 
Ki67-staining giving an estimate of proliferating cells at the 
time points studied. The amount of Ki67 positive cardio-
myocytes was increased during the early post MI period at 
week 1 post MI in the infarct border zone but not in the 
remote myocardium.
The fraction of cardiomyocytes labelled by Ki67 was 
higher than the fraction of BrdU-labelled cardiomyocytes. 
This somewhat unexpected finding may result from the fact 
that BrdU was administered in drinking water instead of 
daily injections. Slow delivery of BrdU from drinking 
water might favour its uptake in rapidly proliferating tis-
sues, limiting its actual delivery to cardiac cells.
Treatment with the AT1 receptor blocker (ARB) losartan 
did not further increase the formation or proliferation of 
cardiomyocytes in the infarct area compared with vehicle 
treated rats with MI as judged by BrdU and Ki67 stainings. 
The BrdU method may underestimate the total number of 
new cardiomyocytes generated during the study period if 
apoptotic or necrotic cardiomyocyte loss is accelerated at 
the same time. However, the rate of apoptosis in the infarct 
border zone did not differ between losartan and vehicle 
treated MI rats. The number of c-Kit positive cardiac stem/
progenitor cells remained unchanged as well. No clear sites 
of accumulation of c-Kit positive cells were found in the 
MI rats at the areas and time points analysed in the present 
experiment.
Figure 1. The number (%) of BrdU+ cardiomyocytes (a) and all BrdU+ cells (b) in the left myocardium after myocardial infarction 
(MI) (n=9–10 at weeks 1 and 4, respectively).
*p<0.05, **p<0.01 versus sham operated group (n=8–7 at weeks 1 and 4, respectively).
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The role of the RAS in the regulation of cardiac remodel-
ling and repair after myocardial injury is complex and still 
poorly understood.11 Expression of several components of 
RAS, including AT1-receptors, is up-regulated in the infarct 
area13,14 suggesting an important role for the local cardiac 
RAS in the scar formation, inflammatory response and 
repair of the damaged myocardium after MI.21 In theory, 
AT1-receptor blockade may have both negative and positive 
effects on the cardiac reparative process after MI. By inhib-
iting the well established growth promoting effects of angio-
tensin II ARBs could even prevent neo-formation of 
cardiomyocytes. On the other hand, the effects of angioten-
sin II and other angiotensin peptides on non-AT1 receptors, 
notably AT2 and angiotensin 1-7 (Mas) receptors, are not 
blocked by ARBs. These non-AT1-mediated effects have 
been suggested to counterbalance the AT1 receptor medi-
ated effects of angiotensin II.22 Thus, the net effect of RAS 
blockade using specific ARBs like losartan on the myocar-
dial healing and repair after MI is likely to be complex and 
multifaceted. According to present results treatment with an 
ARB does not specifically influence the generation of new 
cardiomyocytes after MI.
AT1 receptor mediated effects of angiotensin II have 
been found to stimulate angiogenesis in several disease 
models.26 However, studies elucidating the role of AT1 
receptors in the regulation of angiogenesis after MI have 
Table 3. Amount of proliferating and apoptotic cardiomyocytes at one and four weeks after sham operation or coronary artery 
ligation.
Group Proliferating (Ki67+) 
cardiomyocytes (%)
Apoptotic (Casp3+) 
cardiomyocytes (%)
Week 1
 Sham + vehicle 0.0282±0.0063 (n = 6) 0.0021±0.0013 (n = 5)
 Sham + losartan 0.0095±0.0024 (n = 4) 0.0044±0.0012 (n = 7)
MI + vehicle
 border 0.1405±0.046a (n = 6) 0.0280±0.0124 (n = 9)
 remote 0.0729±0.0352 (n = 6) 0.0154±0.0040a (n = 9)
MI + losartan
 border 0.1700±0.0897 (n = 9) 0.0427±0.0099a (n = 10)
  remote 0.0296±0.0096 (n = 9) 0.0069±0.0034 (n = 10)
Week 4
 Sham + vehicle 0.0038±0.0020 (n = 5) 0.0030±0.0012 (n = 5)
 Sham + losartan 0.0046+0.0022 (n = 7) 0.0023+0.0014 (n = 6)
MI + vehicle
 border 0.0516±0.0228 (n = 10) 0.0224±0.0047a (n = 10)
 remote 0.0153±0.0077 (n = 10) 0.0031±0.0013 (n = 10)
MI + losartan
 border 0.0464±0.0240 (n = 10) 0.0514±0.0137a (n = 10)
 remote 0.0060±0.0032 (n = 10) 0.0029±0.0015 (n = 10)
Values are mean ± SEM.
MI: myocardial infarction.
ap<0.05 versus vehicle treated sham group at corresponding time point.
Table 4. Vascular density and neovascularization four weeks after myocardial infarction (MI).
Group Capillary density
(vWF+ capillaries)
Vascular density
(α SMA+ vessels)
New capillaries
(BrdU+/vWF+ 
capillaries)
New capillaries
(% of total)
New larger vessels 
(BrdU+/α SMA+)
New larger vessels
(% of total)
MI + vehicle (n = 8)
 Border 1072±160 122±13.4 20.2±6.36 1.51±0.342 1.17±0.768 0.749±0.508
 Infarct 112±79.8 433±36.8 6.83±1.84 13.9±4.66 33.7±4.59 8.35±1.39
 Remote 1315±193 97.0±10.4 7.29±1.79 0.470±0.102 1.17±0.768 1.84±1.36
MI + losartan (n = 11)
 Border 1418±61.2a 103±13.6 20.5±5.81 1.47±0.395 3.25±0.899 3.85±1.19a
 Infarct 34.6±7.38 471±31.8 5.73±1.19 22.8±6.05 41.2±5.88 9.25±1.45
 Remote 1726±91.6 97.0±11.0 8.72±2.94 0.528±0.177 0.854±0.854 1.12±1.12
Values are mean ± SEM and results are reported as vessel count per mm2.
ap<0.05 versus same area in vehicle treated MI group.
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been contradictory, suggesting both stimulatory21 and sup-
pressive27 effects of angiotensin II on angiogenesis in the 
infarcted myocardium. In the present study, AT1 receptor 
blockade with losartan induced an increase both in capil-
lary density and in BrdU+ vascular density in the infarct 
border zone compared with vehicle treated rats with MI. 
We also studied gene expression of VEGF and other poten-
tial factors mediating the effects of angiotensin II on angio-
genesis utilizing real time RT-PCR, RT-PCR array 
(unpublished results) and Western blotting, but no changes 
in the gene expression of proangiogenic cytokines or 
growth factors in losartan treated MI rats compared with 
vehicle treated controls were found. This suggests that 
other factors are also involved in the regulation of 
neo-vascularization in the peri-infarct area after MI. 
Alternatively, the time points chosen, that is, one and four 
weeks after coronary ligation, were not optimal to demon-
strate the possible link between angiotensin II and proan-
giogenic cytokines after MI in the present experiment.
As expected, cardiac systolic function was compro-
mised in coronary ligated rats with MI, which averaged 
35–40% of the left ventricle in the present experiment. 
Losartan treatment did not improve systolic function, 
evaluated by echocardiography, during the early post-MI 
period studied. It is tempting to speculate that this result 
in fact reflects the lacking efficacy of losartan on cardio-
myocyte regeneration in this experiment. This is in line 
with clinical post-MI studies in which no clear benefits 
Figure 2. The effect of losartan treatment on the formation of BrdU+ cardiomyocytes (a) and on the number (%) of all BrdU+ 
cells in the left myocardium (b) after myocardial infarction (MI) (n=10 at weeks 1 and 4). C: control; refers to corresponding vehicle 
treated MI rats (n=9–10 at weeks 1 and 4, respectively).
*p=0.08 versus vehicle treated MI group at week 4.
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with ARBs, at least when compared with established treat-
ment of post-MI heart failure including ACE-inhibitors,28,29 
have been obtained.
The effects of angiotensin blockade on cardiac tissue 
after MI appeared to be different in infarcted and non-
infarcted myocardium, as suggested by Sun.11 Contrary to 
the less evident effects of losartan on cardiac tissue changes 
in the infarct zone, losartan treatment influenced the non-
infarcted, remote myocardial in several ways. The observed 
increase in relative cardiac weight after MI in vehicle 
treated rats was completely prevented in rats treated with 
losartan. The myocyte cross-sectional area tended to be 
smaller in losartan treated rats, suggesting inhibitory effects 
on cardiomyocyte and left ventricular hypertrophy as 
reported previously in experimental and clinical studies 
with ARBs.16–18,30 In addition, the overall increase in cell 
proliferation after MI, as judged from the amount of all 
BrdU positive cells in the remote myocardium outside the 
infarct area, did not differ from sham-operated controls in 
the losartan treated rats with MI. These effects on post-MI 
cardiac remodelling and cell proliferation are in agreement 
with previous studies showing that treatment with ARBs 
modulates the adverse remodelling of the non-infarcted 
myocardium after MI.31–33 ARBs have also been shown to 
prevent development of interstitial and perivascular fibro-
sis after MI (not studied in the present experiment). 
Interestingly, relative lung weight was lower in losartan 
treated rats with MI compared with corresponding vehicle 
treated controls, suggesting improved overall cardiac func-
tion, although separate echocardiographic parameters did 
not differ significantly between losartan and vehicle treated 
MI groups. In the long term treatment of chronic heart fail-
ure following myocardial injury the modulating effects of 
AT1 receptor blockade on post MI remodelling are consid-
ered to be beneficial in reducing the occurrence of adverse 
cardiac events.15,18
Figure 3. Cardiomyocyte regeneration and neo-vascularization after MI. (a) and (b) Newly formed BrdU+ (green)/troponin+ (red) 
cardiomyocyte (arrow) in the infarct border zone after MI. (c) Newly formed BrdU+ (green)/vWF+ (red) vascular structure (arrows) 
in the infarct border zone after MI. (d) Proliferating Ki67+ (brown) and MHC+ (red) cardiomyocyte (arrow).
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In summary, the number of BrdU-labelled cardiomyo-
cytes increased markedly in the infarct border zone after 
coronary artery ligation. The enhanced formation of new 
cardiomyocytes continued throughout the four-week post 
MI study period. Treatment with the AT1 receptor antago-
nist losartan neither stimulated nor prevented cardiomyo-
cyte regeneration. On the other hand, AT1 receptor 
blockade stimulated formation of new vascular structures, 
inducing an increase both in capillary and BrdU+ vascular 
density in the infarct border zone compared with vehicle 
treated rats with MI. In addition, losartan effectively 
influenced remodelling of the non-infarcted myocardium, 
preventing completely post MI cardiac hypertrophy. In 
future studies, RAS blockade should be tested in combi-
nation with specific tools to stimulate cardiac regenera-
tion,19,20 aiming at both prevention of the adverse 
remodelling of the non-infarcted myocardium and, at the 
same time, facilitation of repair of the injured peri-infarct 
zone after myocardial infarction.
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